Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nuvation Bio Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. While these actions are both located within 1 distinct art unit, they are being reviewed by 2 distinct examiners. This distribution suggests that even though the technical subject matter is closely related, the company must navigate the individual perspectives and examination styles of 2 different people at the patent office.
The busiest examiner for the portfolio is WARD, PAUL V, who is responsible for 1 pending office action. This indicates that the workload is split, with each of the 2 distinct examiners handling 1 pending office action. For practitioners, this means that while the technical standards of the 1 distinct art unit will be consistent, the specific feedback and requirements may vary between the 2 examiners. Managing this diversity within 1 art unit requires a strategy that accounts for different interpretations of the same technical field. The company's current prosecution profile in the Biotechnology & Pharmaceuticals sector is thus characterized by a unified technical focus but a divided examiner oversight, requiring coordination across both pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866777 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | GONZALEZ, LUISALBERTO | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | GONZALEZ, LUISALBERTO | 13d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866777 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | WARD, PAUL V | — | §103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | GONZALEZ, LUISALBERTO | 1624 | §102§112 | Final Rejection | 13d | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial